In:
Frontiers in Microbiology, Frontiers Media SA, Vol. 11 ( 2020-11-24)
Kurzfassung:
Using convalescent plasma as immunotherapy is an old method for treatment of infectious diseases. Several countries have recently allowed the use of such therapy for the treatment of COVID-19 patients especially those who are critically ill. A similar program is currently being tested in Egypt. Here, we tested 227 plasma samples from convalescent donors in Egypt for neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using a microneutralization (MN) assay. A third of the tested samples did not have antibody titers and 58% had titers between 1:10 and 1:80. Only 12% had titers & gt;1:160. We also compared MN assays using different virus concentrations, plaque reduction neutralization (PRNT) assays, and a chemiluminescence assay that measures immunoglobulin G (IgG) binding to N and S proteins of SARS-CoV-2. Our results indicated that a MN assay using 100 TCID50/ml provides comparable results to PRNT and allows for high throughput testing.
Materialart:
Online-Ressource
ISSN:
1664-302X
DOI:
10.3389/fmicb.2020.596851
DOI:
10.3389/fmicb.2020.596851.s001
Sprache:
Unbekannt
Verlag:
Frontiers Media SA
Publikationsdatum:
2020
ZDB Id:
2587354-4